These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 23521149)

  • 1. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
    Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
    J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population.
    Chandra A; Lahiri A; Senapati S; Basu B; Ghosh S; Mukhopadhyay I; Behra A; Sarkar S; Chatterjee G; Chatterjee R
    Sci Rep; 2016 Apr; 6():24059. PubMed ID: 27048876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
    Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
    Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
    Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
    Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
    Batalla A; Coto E; González-Fernández D; González-Lara L; Gómez J; Santos-Juanes J; Queiro R; Coto-Segura P
    Pharmacogenet Genomics; 2015 Jun; 25(6):313-6. PubMed ID: 25794162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
    Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
    Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6.
    Riveira-Munoz E; He SM; Escaramís G; Stuart PE; Hüffmeier U; Lee C; Kirby B; Oka A; Giardina E; Liao W; Bergboer J; Kainu K; de Cid R; Munkhbat B; Zeeuwen PL; Armour JA; Poon A; Mabuchi T; Ozawa A; Zawirska A; Burden AD; Barker JN; Capon F; Traupe H; Sun LD; Cui Y; Yin XY; Chen G; Lim HW; Nair RP; Voorhees JJ; Tejasvi T; Pujol R; Munkhtuvshin N; Fischer J; Kere J; Schalkwijk J; Bowcock A; Kwok PY; Novelli G; Inoko H; Ryan AW; Trembath RC; Reis A; Zhang XJ; Elder JT; Estivill X
    J Invest Dermatol; 2011 May; 131(5):1105-9. PubMed ID: 21107349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.
    De Keyser E; Busard CI; Lanssens S; Meuleman L; Hutten BA; Costanzo A; van den Reek JM; Zweegers J; Lambert J; Spuls PI
    Ther Drug Monit; 2019 Oct; 41(5):634-639. PubMed ID: 31107404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06.
    Bergboer JG; Oostveen AM; de Jager ME; den Heijer M; Joosten I; van de Kerkhof PC; Zeeuwen PL; de Jong EM; Schalkwijk J; Seyger MM
    Br J Dermatol; 2012 Oct; 167(4):922-5. PubMed ID: 22512642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.
    de Cid R; Riveira-Munoz E; Zeeuwen PL; Robarge J; Liao W; Dannhauser EN; Giardina E; Stuart PE; Nair R; Helms C; Escaramís G; Ballana E; Martín-Ezquerra G; den Heijer M; Kamsteeg M; Joosten I; Eichler EE; Lázaro C; Pujol RM; Armengol L; Abecasis G; Elder JT; Novelli G; Armour JA; Kwok PY; Bowcock A; Schalkwijk J; Estivill X
    Nat Genet; 2009 Feb; 41(2):211-5. PubMed ID: 19169253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients.
    Ho SS; Tsai TF
    Mol Diagn Ther; 2022 Sep; 26(5):541-549. PubMed ID: 35789988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.
    Talamonti M; Galluzzo M; Zangrilli A; Papoutsaki M; Egan CG; Bavetta M; Tambone S; Fargnoli MC; Bianchi L
    Mol Diagn Ther; 2017 Jun; 21(3):295-301. PubMed ID: 28130758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPR1 gene near HLA-C is unlikely to be a psoriasis susceptibility gene.
    Chang YT; Tsai SF; Lin MW; Liu HN; Lee DD; Shiao YM; Chin PJ; Wang WJ
    Exp Dermatol; 2003 Jun; 12(3):307-14. PubMed ID: 12823445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.
    West J; Ogston S; Berg J; Palmer C; Fleming C; Kumar V; Foerster J
    Clin Exp Dermatol; 2017 Aug; 42(6):651-655. PubMed ID: 28512993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.